Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531
Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular Dystrophy (DMD), WVE-N531, …
Post
-
-
Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s
Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised monoclonal antibody sabirnetug (ACU193) for …
-
J&J’s NSCLC combo projected to extend survival by one year over Tagrisso
Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by one …
-
Podcast: Perspectives and projections on the 2025 biotech landscape
The biotech industry is experiencing an unprecedented transformation, marked by complex market dynamics, shifting global innovation patterns and evolving investment …
-
IGC Pharma posts promising interim data for Alzheimer’s therapy
IGC Pharma has reported encouraging interim results from its ongoing Phase II CALMA trial (NCT05543681) of IGC-AD1, an investigational treatment …
-
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trial
Epicrispr Biotechnologies has raised $68m in the initial close of its Series B financing round to commence the clinical trial …
-
Duchenne muscular dystrophy: Five trials to watch
The beginning to the year has been eventful in the Duchenne muscular dystrophy (DMD) space, with several trial readouts announced …
-
Unmatched quality in pharmaceutical logistics: Why it matters
Ensuring the integrity of pharmaceutical products is one of the most complex challenges in global healthcare today. From temperature-sensitive biologics …
-
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat, an oral plasma kallikrein inhibitor …
-
Axsome’s Sunosi succeeds in Phase III ADHD trial
Axsome Therapeutics’ Phase III Focus trial investigating its attention-deficit hyperactivity disorder (ADHD) therapy, Sunosi (solriamfetol), has met its primary endpoint …
-
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show …
-
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis
Biotechnology company Tiziana Life Sciences has begun dosing subjects in its placebo-controlled Phase II trial of foralumab, an intranasal fully …
-
Helicore doses first subject in Phase I trial of obesity treatment
US-based biopharmaceutical company Helicore Biopharma has dosed the first subject in a randomised, first-in-human Phase I trial of its humanised …
-
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate …
-
Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57%
Mural Oncology is discontinuing the development of nemvaleukin alfa in ovarian cancer after a Phase III trial failed to improve …
